Local administration of TLR ligands rescues the function of tumor-infiltrating CD8 T cells and enhances the antitumor effect of lentivector immunization.

Local administration of TLR ligands rescues the function of tumor-infiltrating CD8 T cells and enhances the antitumor effect of lentivector immunization.
复制标题

DOI:
10.4049/jimmunol.1203470
复制
发表时间:
2013-06-01
期刊:
Journal of immunology (Baltimore, Md. : 1950)
影响因子:
--
通讯作者:
He Y
He Y
中科院分区:
其他
文献类型:
--
作者:
Xiao H;Peng Y;Hong Y;Huang L;Guo ZS;Bartlett DL;Fu N;Munn DH;Mellor A;He Y

文献摘要

参考文献

被引文献

相似文献

Cancer vaccines, so far, have shown limited effect to control the growth of established tumors due largely to effector failure of the antitumor immune responses. Tumor lesion is characterized as chronic indolent inflammation in which the effector function of tumor infiltrating lymphocytes (TILs) is severely impaired. In this study, we investigated whether the effector function of CD8 TILs could be rescued by converting the chronic inflammation milieu to acute inflammation within tumors. We found that injection of TLR3/9 ligands (PolyI:C/CpG) into a tumor during the effector phase of lentivector (lv) immunization effectively rescued the function of lv-activated CD8 TILs and decreased the percentage of Treg within the tumor, resulting in a marked improvement in the antitumor efficacy of lv immunization. Mechanistically, rescue of the effector function of CD8 TILs by TLR3/9 ligands is likely dependent on production, within a tumor, of type-1 IFN that can mature and activate tumor infiltrating dendritic cells (TIDCs). The effector function of CD8 TILs could not be rescued in mice lacking intact type-I IFN signaling. These findings have important implications for tumor immunotherapy, suggesting that type-I IFN mediated activation of TIDCs within a tumor will likely restore/enhance the effector function of CD8 TILs and thus improve the antitumor efficacy of current cancer vaccines.
DOI: 10.1084/jem.20101159
发表时间: 2011-09-26
期刊: The Journal of experimental medicine
影响因子: --
作者:
Fuertes MB;Kacha AK;Kline J;Woo SR;Kranz DM;Murphy KM;Gajewski TF
通讯作者: Gajewski TF
DOI: 10.1158/0008-5472.can-10-2820
发表时间: 2011-04-01
期刊: Cancer research
影响因子: 11.2
作者:
Burnette BC;Liang H;Lee Y;Chlewicki L;Khodarev NN;Weichselbaum RR;Fu YX;Auh SL
通讯作者: Auh SL
DOI: 10.1038/ni1213
发表时间: 2005-07-01
期刊: NATURE IMMUNOLOGY
影响因子: 30.5
作者:
Dunn, GP;Bruce, AT;Schreiber, RD
通讯作者: Schreiber, RD
DOI: 10.1038/sj.gt.3302697
发表时间: 2006-04-01
期刊: GENE THERAPY
影响因子: 5.1
作者:
Dullaers, M;Van Meirvenne, S;Breckpot, K
通讯作者: Breckpot, K
DOI: 10.1586/14760584.3.5.563
发表时间: 2004-10-01
影响因子: 6.2
作者:
Elsawa, Sherine F;Rodeberg, David A;Celis, Esteban
通讯作者: Celis, Esteban